Janux Therapeutics Inc
NASDAQ:JANX
Intrinsic Value
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. [ Read More ]
The intrinsic value of one JANX stock under the Base Case scenario is 2.22 USD. Compared to the current market price of 56.08 USD, Janux Therapeutics Inc is Overvalued by 96%.
Valuation Backtest
Janux Therapeutics Inc
Run backtest to discover the historical profit from buying and selling JANX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Janux Therapeutics Inc
Current Assets | 349.2m |
Cash & Short-Term Investments | 344m |
Other Current Assets | 5.2m |
Non-Current Assets | 31.2m |
PP&E | 27.8m |
Other Non-Current Assets | 3.3m |
Current Liabilities | 13m |
Accounts Payable | 2.4m |
Accrued Liabilities | 8.9m |
Other Current Liabilities | 1.7m |
Non-Current Liabilities | 23m |
Other Non-Current Liabilities | 23m |
Earnings Waterfall
Janux Therapeutics Inc
Revenue
|
8.1m
USD
|
Operating Expenses
|
-81.1m
USD
|
Operating Income
|
-73m
USD
|
Other Expenses
|
14.7m
USD
|
Net Income
|
-58.3m
USD
|
Free Cash Flow Analysis
Janux Therapeutics Inc
JANX Profitability Score
Profitability Due Diligence
Janux Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Janux Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
JANX Solvency Score
Solvency Due Diligence
Janux Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Janux Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JANX Price Targets Summary
Janux Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for JANX is 57.46 USD with a low forecast of 25.25 USD and a high forecast of 105 USD.
Ownership
JANX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
JANX Price
Janux Therapeutics Inc
Average Annual Return | -5.84% |
Standard Deviation of Annual Returns | 35.21% |
Max Drawdown | -83% |
Market Capitalization | 2.9B USD |
Shares Outstanding | 51 660 100 |
Percentage of Shares Shorted | 14.23% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2021-06-11. The firm is engaged in developing therapeutics based on its Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. Its focus is on developing a class of T cell engagers (TCEs). The company is developing a broad pipeline with programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Its pipeline includes PSMA-TRACTr, EGFR-TRACTr and TROP2-TRACTr. The firm's PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. Its EGFR-TRACTr is designed to target EGFR. TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target. The firm is also applying its technology to develop a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and CD28.
Contact
IPO
Employees
Officers
The intrinsic value of one JANX stock under the Base Case scenario is 2.22 USD.
Compared to the current market price of 56.08 USD, Janux Therapeutics Inc is Overvalued by 96%.